| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers M > Headlines for MIV Therapeutics Inc. > News item |
MIV's stroke-prevention implant looks promising, animal study shows
By Angela McDaniels
Seattle, Dec. 2 - MIV Therapeutics Inc. said preclinical study results reinforce the potential of the company's Aortic Embolic Protection Device filtration device to prevent strokes.
Once positioned in the aorta, the device functions as a filter to prevent migration of embolic particles and blood clots to blood vessels supplying the brain and thus prevent strokes.
The study was designed to measure the device's safety and to confirm critical positioning and performance following implantation in the aorta. The results of the study performed on sheep under varying conditions are considered medically significant and reinforce the device's potential as a viable preventive tool to fight strokes in cardiac patients, the company said.
"Our technology is at the cutting-edge of scientific development in the prevention of cardio-embolic stroke, but the success of our stroke-prevention devices is rooted in their functional simplicity and ease of use," said Dov Shimon, SagaX chief executive officer, in a company news release.
MIV's SagaX subsidiary is developing the device, and the animal studies with the device are being performed at the Hadassah University Hospital in Jerusalem.
The market for implantable stroke prevention devices is expanding rapidly worldwide and could grow into a $500 million to $1 billion market segment in the next few years, the company said.
Stroke is the third-leading cause of death and the leading cause of severe disability in the world, the company said.
MIV is based in Vancouver, B.C., and develops biocompatible coatings and advanced drug-delivery systems.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.